A number of trials have been conducted with each of the three main antipneumococcal respiratory fluoroquinolones. In an open-label, noncomparative study, gemifloxacin (320 mg, once daily for 7 ...
Perspective from Monica I. Ardura, DO, MSCS Fluoroquinolone exposure did not appear to increase the risk for developing vancomycin-resistant Enterococcus colonization following pediatric ...
A literature search was conducted to evaluate the pharmacokinetic and pharmacodynamic profile of the respiratory fluoroquinolones (gemifloxacin, levofloxacin and moxifloxacin) and their efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results